We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Intelsius Launches Extreme Exposure Range to Maintain Sample Integrity

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Intelsius has announced the launch of the new Xtremotherm™ - Defying Extremes™ range of products.

Xtremotherm™ Extreme Exposure Systems range of shipping solutions protects ambient patient samples in extreme climates.

Xtremotherm solutions are designed to protect critical patient sample payloads against degradation during periods of extreme temperature exposures that are common during shipment due to increasingly remote clinical sites.

“The time-sensitive nature of clinical research and extraordinary costs involved in getting a drug or treatment to market, make the Xtremotherm products an excellent choice for extreme temperature environments,” said David Walsh, chief executive officer of Intelsius.

“Xtremotherm products were created to protect the enormous investments made in research and development around the world including emerging markets such as Brazil, China, India and Russia,” said Walsh.

As ambient samples are typically not temperature monitored during transport, our Pharma clients can now deploy the best available protection to ensure the sample is viable despite being transported through periods of extreme temperature.

“The loss of a single sample is simply not acceptable from either an ethical or financial perspective. We owe it to the patients to ensure their samples are received at the labs in optimum condition,” said Walsh.

These Intelsius packaging solutions are certified for time ranges from four hours to 38 hours at constant external temperatures of -30°C to +40°C.

In particular, Xtremotherm-5 is unique in that it utilizes proprietary patent pending PRA (Peak Ratio Algorithm) Technology™ that delivers the absolute optimal size for maximum performance.

“With Phase III per patient clinical trial costs set to reach nearly $50,000, minimizing risk of sample deletion is paramount to study success and hitting deadlines,” said Walsh.